The PGNX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PGNX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The PGNX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View PGNX Detailed Price Forecast - CNN Money||View PGNX Detailed Summary - Google Finance|
|View PGNX Detailed Summary - Yahoo! Finance||View PGNX Stock Research & Analysis - Zacks.com|
|View PGNX Trends & Analysis - Trade-Ideas||View PGNX Major Holders - Barrons|
|View PGNX Call Transcripts - NASDAQ||View PGNX Breaking News & Analysis - Seeking Alpha|
|View PGNX Annual Report - CompanySpotlight.com||View PGNX OTC Short Report - OTCShortReport.com|
|View PGNX Fundamentals - TradeKing||View PGNX SEC Filings - Bar Chart|
|View Historical Prices for PGNX - The WSJ||View Performance/Total Return for PGNX - Morningstar|
|View the Analyst Estimates for PGNX - MarketWatch||View the Earnings History for PGNX - CNBC|
|View the PGNX Earnings - StockMarketWatch||View PGNX Buy or Sell Recommendations - MacroAxis|
|View the PGNX Bullish Patterns - American Bulls||View PGNX Short Pain Metrics - ShortPainBot.com|
|View PGNX Stock Mentions - StockTwits||View PGNX Stock Mentions - PennyStockTweets|
|View PGNX Stock Mentions - Twitter||View PGNX Investment Forum News - Investor Hub|
|View PGNX Stock Mentions - Yahoo! Message Board||View PGNX Stock Mentions - Seeking Alpha|
|View Insider Transactions for PGNX - SECform4.com||View Insider Transactions for PGNX - Insider Cow|
|View PGNX Major Holdings Summary - CNBC||View Insider Disclosure for PGNX - OTC Markets|
|View Insider Transactions for PGNX - Yahoo! Finance||View Institutional Holdings for PGNX - NASDAQ|
|View PGNX Stock Insight & Charts - FinViz.com||View PGNX Investment Charts - StockCharts.com|
|View PGNX Stock Overview & Charts - BarChart||View PGNX User Generated Charts - Trading View|
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Posted on Wednesday August 15, 2018
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Analysts Remain Bullish on Nektar Stock in August
Posted on Tuesday August 14, 2018
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
Opko Health: Q2 Expenditures, Developments, Recommendations
Posted on Thursday August 09, 2018
In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.
How Opko Health Fared in the Second Quarter of 2018
Posted on Thursday August 09, 2018
In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.